| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor Protein-Tyrosine Kinases | 4 | 2018 | 156 | 1.540 |
Why?
|
| Lung Neoplasms | 11 | 2018 | 2365 | 1.010 |
Why?
|
| Glucuronosyltransferase | 7 | 2008 | 184 | 0.930 |
Why?
|
| Exons | 5 | 2018 | 450 | 0.830 |
Why?
|
| Alternative Splicing | 2 | 2018 | 219 | 0.610 |
Why?
|
| Vitamin D Deficiency | 6 | 2018 | 107 | 0.610 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 255 | 0.600 |
Why?
|
| Extracellular Space | 1 | 2017 | 88 | 0.530 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 894 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-met | 6 | 2010 | 199 | 0.500 |
Why?
|
| Protein Isoforms | 1 | 2017 | 295 | 0.500 |
Why?
|
| Serotonin | 3 | 2005 | 209 | 0.420 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 893 | 0.420 |
Why?
|
| Trigonella | 1 | 2012 | 1 | 0.380 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.380 |
Why?
|
| Calcitriol | 1 | 2013 | 173 | 0.370 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 61 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2015 | 2484 | 0.350 |
Why?
|
| Vitamin D | 5 | 2018 | 272 | 0.350 |
Why?
|
| Phytotherapy | 1 | 2012 | 137 | 0.350 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 270 | 0.330 |
Why?
|
| Plant Extracts | 1 | 2012 | 247 | 0.330 |
Why?
|
| Autophagy | 1 | 2012 | 172 | 0.330 |
Why?
|
| Insulin Resistance | 1 | 2013 | 379 | 0.330 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 2755 | 0.320 |
Why?
|
| Glucuronides | 5 | 2008 | 34 | 0.320 |
Why?
|
| Liver | 4 | 2013 | 1210 | 0.280 |
Why?
|
| Saudi Arabia | 9 | 2019 | 17 | 0.270 |
Why?
|
| Pregnancy Trimester, First | 2 | 2018 | 63 | 0.250 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2015 | 129 | 0.250 |
Why?
|
| Hydroxytryptophol | 1 | 2004 | 1 | 0.220 |
Why?
|
| ErbB Receptors | 4 | 2011 | 506 | 0.210 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 166 | 0.210 |
Why?
|
| Obesity | 4 | 2014 | 1018 | 0.190 |
Why?
|
| Humans | 33 | 2019 | 93511 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2014 | 811 | 0.170 |
Why?
|
| Paxillin | 2 | 2013 | 59 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 1133 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2465 | 0.160 |
Why?
|
| Receptors, Growth Factor | 2 | 2010 | 52 | 0.150 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2019 | 7 | 0.150 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1117 | 0.140 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 49 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2018 | 131 | 0.130 |
Why?
|
| Biomarkers | 5 | 2019 | 1910 | 0.130 |
Why?
|
| Pharmacogenetics | 3 | 2005 | 456 | 0.120 |
Why?
|
| Child | 8 | 2019 | 7355 | 0.120 |
Why?
|
| Adolescent | 9 | 2018 | 9606 | 0.120 |
Why?
|
| Male | 16 | 2018 | 44553 | 0.120 |
Why?
|
| Dairy Products | 1 | 2015 | 13 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2005 | 3829 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 962 | 0.110 |
Why?
|
| Sequence Deletion | 1 | 2015 | 209 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2015 | 108 | 0.110 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 227 | 0.100 |
Why?
|
| Genotype | 3 | 2009 | 1866 | 0.100 |
Why?
|
| Adult | 13 | 2018 | 27918 | 0.100 |
Why?
|
| Oxazepam | 2 | 2004 | 3 | 0.100 |
Why?
|
| Microsomes, Liver | 2 | 2004 | 48 | 0.100 |
Why?
|
| Calcium | 2 | 2015 | 1176 | 0.100 |
Why?
|
| Middle Aged | 11 | 2018 | 27569 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 557 | 0.100 |
Why?
|
| Piperazines | 3 | 2009 | 284 | 0.100 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2013 | 18 | 0.100 |
Why?
|
| Indoles | 3 | 2009 | 303 | 0.100 |
Why?
|
| Receptor, Insulin | 1 | 2013 | 60 | 0.100 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 56 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 292 | 0.100 |
Why?
|
| Eugenol | 1 | 2012 | 2 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2012 | 3 | 0.100 |
Why?
|
| Guaiacol | 1 | 2012 | 3 | 0.100 |
Why?
|
| Benzaldehydes | 1 | 2012 | 4 | 0.100 |
Why?
|
| Sesquiterpenes | 1 | 2012 | 13 | 0.100 |
Why?
|
| Catechols | 1 | 2012 | 8 | 0.100 |
Why?
|
| Female | 15 | 2018 | 48698 | 0.100 |
Why?
|
| Fatty Alcohols | 1 | 2012 | 10 | 0.100 |
Why?
|
| Sulfonamides | 3 | 2009 | 331 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 291 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2004 | 363 | 0.090 |
Why?
|
| Jurkat Cells | 1 | 2012 | 84 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 352 | 0.090 |
Why?
|
| Focal Adhesions | 1 | 2013 | 66 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 304 | 0.090 |
Why?
|
| Muscles | 1 | 2013 | 184 | 0.090 |
Why?
|
| Vacuoles | 1 | 2012 | 48 | 0.090 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 59 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1518 | 0.090 |
Why?
|
| Calcifediol | 1 | 2012 | 22 | 0.090 |
Why?
|
| Seeds | 1 | 2012 | 62 | 0.090 |
Why?
|
| Sunlight | 1 | 2012 | 27 | 0.090 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 131 | 0.090 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 135 | 0.090 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 68 | 0.090 |
Why?
|
| Body Weight | 1 | 2013 | 449 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 185 | 0.090 |
Why?
|
| Aged | 7 | 2012 | 20430 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 543 | 0.080 |
Why?
|
| Cell Line | 2 | 2012 | 2464 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2013 | 270 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 353 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 730 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2010 | 37 | 0.080 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.080 |
Why?
|
| Animals | 8 | 2014 | 28155 | 0.080 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 555 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 666 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1847 | 0.070 |
Why?
|
| PAX5 Transcription Factor | 1 | 2009 | 33 | 0.070 |
Why?
|
| Exercise | 1 | 2012 | 353 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1914 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 715 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 297 | 0.070 |
Why?
|
| Vulva | 1 | 2008 | 23 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 85 | 0.070 |
Why?
|
| Mutation | 5 | 2013 | 4272 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 381 | 0.070 |
Why?
|
| Risk Factors | 5 | 2018 | 5898 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 216 | 0.060 |
Why?
|
| Phenotype | 3 | 2015 | 2544 | 0.060 |
Why?
|
| Nutritional Status | 2 | 2018 | 79 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 641 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 1077 | 0.060 |
Why?
|
| Mice | 4 | 2014 | 12269 | 0.060 |
Why?
|
| Prevalence | 3 | 2015 | 1321 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 751 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3435 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1225 | 0.060 |
Why?
|
| Prognosis | 2 | 2012 | 3910 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 988 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2026 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2003 | 272 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2009 | 1353 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 603 | 0.050 |
Why?
|
| Rats, Gunn | 1 | 2004 | 2 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 826 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 20 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 109 | 0.050 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2004 | 17 | 0.050 |
Why?
|
| Cats | 1 | 2004 | 285 | 0.050 |
Why?
|
| Bupropion | 1 | 2004 | 21 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 44 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2004 | 300 | 0.050 |
Why?
|
| Triglycerides | 2 | 2015 | 231 | 0.050 |
Why?
|
| Gene Dosage | 3 | 2009 | 211 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1660 | 0.050 |
Why?
|
| Microsomes | 1 | 2003 | 32 | 0.050 |
Why?
|
| Haplotypes | 1 | 2005 | 647 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 23 | 0.050 |
Why?
|
| Insecta | 1 | 2003 | 55 | 0.050 |
Why?
|
| Cholesterol | 2 | 2015 | 364 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2802 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 1073 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2004 | 333 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 6930 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 1105 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 302 | 0.040 |
Why?
|
| Transfection | 2 | 2014 | 880 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 526 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 273 | 0.040 |
Why?
|
| Pregnancy | 2 | 2018 | 3147 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1906 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 7061 | 0.040 |
Why?
|
| Fitness Centers | 1 | 2018 | 1 | 0.040 |
Why?
|
| Rats | 1 | 2004 | 4072 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 232 | 0.030 |
Why?
|
| Fasting | 1 | 2018 | 163 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 2303 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2012 | 884 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 729 | 0.030 |
Why?
|
| RNA Interference | 2 | 2008 | 379 | 0.030 |
Why?
|
| Parents | 1 | 2019 | 292 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 711 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2015 | 3 | 0.030 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 3 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 624 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 28 | 0.030 |
Why?
|
| Endoglin | 1 | 2014 | 20 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 83 | 0.030 |
Why?
|
| Eating | 1 | 2015 | 162 | 0.030 |
Why?
|
| Apoptosis | 2 | 2012 | 1721 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 307 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 867 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 271 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 315 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1701 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 208 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2015 | 700 | 0.020 |
Why?
|
| Kinetics | 2 | 2008 | 1492 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 476 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 25 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 39 | 0.020 |
Why?
|
| Lipocalins | 1 | 2012 | 34 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 36 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2014 | 476 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2015 | 337 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 300 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 37 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 21 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 167 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 304 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 173 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 134 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 293 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 241 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2014 | 3502 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 25 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 413 | 0.020 |
Why?
|
| Allelic Imbalance | 1 | 2011 | 22 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 120 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 656 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 696 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2014 | 439 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 77 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 84 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 373 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 1004 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 352 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1133 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 274 | 0.020 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2009 | 34 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 531 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 24 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 50 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 40 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2008 | 13 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 809 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2008 | 65 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 784 | 0.020 |
Why?
|
| Rifampin | 1 | 2008 | 22 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2008 | 43 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 254 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 712 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 361 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2008 | 77 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 186 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 280 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2008 | 279 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 587 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 824 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 290 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 4560 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 568 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2008 | 144 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 203 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 603 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1931 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2220 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 813 | 0.020 |
Why?
|
| Nicotine | 1 | 2008 | 208 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 572 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2008 | 245 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 767 | 0.010 |
Why?
|
| Lung | 1 | 2012 | 1366 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1173 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1799 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 556 | 0.010 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2004 | 19 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1338 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2002 | 40 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 102 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 307 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1741 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 948 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1139 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 2544 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1953 | 0.010 |
Why?
|
| Neoplasms | 1 | 2009 | 3169 | 0.010 |
Why?
|